244 related articles for article (PubMed ID: 32259641)
1. New Advances in Molecular Breast Cancer Pathology.
Rakha EA; Pareja FG
Semin Cancer Biol; 2021 Jul; 72():102-113. PubMed ID: 32259641
[TBL] [Abstract][Full Text] [Related]
2. Molecular classification of breast cancer: what the pathologist needs to know.
Rakha EA; Green AR
Pathology; 2017 Feb; 49(2):111-119. PubMed ID: 28040199
[TBL] [Abstract][Full Text] [Related]
3. An update on the pathological classification of breast cancer.
Rakha EA; Tse GM; Quinn CM
Histopathology; 2023 Jan; 82(1):5-16. PubMed ID: 36482272
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine.
De Abreu FB; Wells WA; Tsongalis GJ
Am J Pathol; 2013 Oct; 183(4):1075-1083. PubMed ID: 23920325
[TBL] [Abstract][Full Text] [Related]
5. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
[TBL] [Abstract][Full Text] [Related]
6. Molecular tests as prognostic factors in breast cancer.
van de Vijver MJ
Virchows Arch; 2014 Mar; 464(3):283-91. PubMed ID: 24487789
[TBL] [Abstract][Full Text] [Related]
7. Molecular classification of breast cancer.
Vuong D; Simpson PT; Green B; Cummings MC; Lakhani SR
Virchows Arch; 2014 Jul; 465(1):1-14. PubMed ID: 24878755
[TBL] [Abstract][Full Text] [Related]
8. The changing role of pathologists from morphologists to molecular pathologists in the era of precision medicine.
Masood S
Breast J; 2020 Jan; 26(1):27-34. PubMed ID: 31876097
[TBL] [Abstract][Full Text] [Related]
9. Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer.
Rakha EA; Soria D; Green AR; Lemetre C; Powe DG; Nolan CC; Garibaldi JM; Ball G; Ellis IO
Br J Cancer; 2014 Apr; 110(7):1688-97. PubMed ID: 24619074
[TBL] [Abstract][Full Text] [Related]
10. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer prognostic classification in the molecular era: the role of histological grade.
Rakha EA; Reis-Filho JS; Baehner F; Dabbs DJ; Decker T; Eusebi V; Fox SB; Ichihara S; Jacquemier J; Lakhani SR; Palacios J; Richardson AL; Schnitt SJ; Schmitt FC; Tan PH; Tse GM; Badve S; Ellis IO
Breast Cancer Res; 2010; 12(4):207. PubMed ID: 20804570
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer intratumour heterogeneity: current status and clinical implications.
Joseph C; Papadaki A; Althobiti M; Alsaleem M; Aleskandarany MA; Rakha EA
Histopathology; 2018 Nov; 73(5):717-731. PubMed ID: 29722058
[TBL] [Abstract][Full Text] [Related]
13. Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine.
Aleskandarany MA; Vandenberghe ME; Marchiò C; Ellis IO; Sapino A; Rakha EA
Pathobiology; 2018; 85(1-2):23-34. PubMed ID: 29428954
[TBL] [Abstract][Full Text] [Related]
14. MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology.
Mittempergher L; Delahaye LJMJ; Witteveen AT; Spangler JB; Hassenmahomed F; Mee S; Mahmoudi S; Chen J; Bao S; Snel MHJ; Leidelmeijer S; Besseling N; Bergstrom Lucas A; Pabón-Peña C; Linn SC; Dreezen C; Wehkamp D; Chan BY; Bernards R; van 't Veer LJ; Glas AM
J Mol Diagn; 2019 Sep; 21(5):808-823. PubMed ID: 31173928
[TBL] [Abstract][Full Text] [Related]
15. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
[TBL] [Abstract][Full Text] [Related]
16. Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes.
Donovan MJ; Cordon-Cardo C
Mol Diagn Ther; 2017 Apr; 21(2):115-123. PubMed ID: 28000172
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Late Recurrence and Distant Metastasis in Early-stage Breast Cancer: Overview of Current and Emerging Biomarkers.
Gouri A; Benarba B; Dekaken A; Aoures H; Benharkat S
Curr Drug Targets; 2020; 21(10):1008-1025. PubMed ID: 32164510
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation and breast cancer: A way forward (Review).
Vietri MT; D'Elia G; Benincasa G; Ferraro G; Caliendo G; Nicoletti GF; Napoli C
Int J Oncol; 2021 Nov; 59(5):. PubMed ID: 34726251
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathology of breast cancer: the journey from traditional practice toward embracing the complexity of a molecular classification.
Gruver AM; Portier BP; Tubbs RR
Arch Pathol Lab Med; 2011 May; 135(5):544-57. PubMed ID: 21526953
[TBL] [Abstract][Full Text] [Related]
20. Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.
Turner BM; Hicks DG
Biotech Histochem; 2017; 92(3):175-200. PubMed ID: 28318327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
